Loading...
01/09 22:00
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals. Positive factors include strong growth in the German market, improved operational efficiency, and reduced losses. However, risks like supply chain challenges, regulatory issues, and competitive pressures counterbalance these positives. No guidance was provided, and there is no share buyback program to boost investor confidence. Given these factors, the stock price is likely to remain stable, resulting in a neutral prediction.
Revenue Q3 2024 $13.9 million, an increase of 12.2% compared to $12.4 million in Q3 2023, driven mainly by a 278% increase in German revenue.
Operating Expenses Q3 2024 $4.1 million, a decrease of 16% compared to $4.9 million in Q3 2023, attributed to decreased salaries, depreciation, and insurance costs.
Operating Expenses Ratio Q3 2024 30%, improved from 40% in Q3 2023, reflecting increased efficiency due to lower operational costs and increased revenue.
Gross Profit Q3 2024 $3.1 million, an increase of 19% compared to $2.6 million in Q3 2023, driven by higher sales.
Net Loss Q3 2024 $1.1 million, a decrease from $2.1 million in Q3 2023, indicating improved financial performance.
Diluted Loss per Share Q3 2024 $0.41, compared to a loss of $0.96 per share in Q3 2023, reflecting reduced losses.
Cash and Cash Equivalents as of September 30, 2024 $2 million, an increase from $1.8 million on December 31, 2023.
Total Assets as of September 30, 2024 $44.6 million, a decrease of 8.6% from $48.8 million on December 31, 2023, mainly due to the Oranim agreement cancellation.
Total Liabilities as of September 30, 2024 $40.4 million, an increase of 15% from $35.1 million on December 31, 2023, primarily due to the Oranim agreement cancellation.
Non-IFRS Adjusted EBITDA Loss Q3 2024 $0.2 million, improved from an EBITDA loss of $1.3 million in Q3 2023, indicating better operational efficiency.
New Product Launches: In Q3, the company relaunched LOT420, a premium Canadian brand with three strains, which were well received in the market.
Sales Performance of New Products: The three strains launched under LOT420 sold through quickly, indicating strong market demand.
Market Expansion in Germany: Sales in Germany increased by over 200% in Q2 versus Q1 to reach $3.5 million, and further increased by 66% in Q3 to reach $5.8 million.
Market Positioning in Germany: The company is positioned among the top cannabis companies in Germany, driven by the growth in the medical cannabis market.
Operational Efficiency: Operating expenses decreased from $4.9 million in Q3 2023 to $4.1 million in Q3 2024, resulting in a 25% increase in efficiency.
Cost Management: Active cost management across all business aspects has significantly lowered costs, contributing to improved operational efficiency.
Strategic Shift: The company has concentrated resources on the German market, which has proven to be a successful strategic shift.
Team Integration: The integration of Israeli and German teams has been a focus, aimed at building a strong supply chain and improving resource management.
Market Growth Risks: The rapid growth of the German cannabis market may lead to increased competition, which could pressure pricing and market share.
Supply Chain Challenges: The ongoing war in Israel has caused delays in shipments, impacting the supply chain and potentially affecting revenue.
Regulatory Issues: Changes brought about by the July 2024 reform in Israel are causing complications in the prescription process, leading to a decline in the number of medical cannabis patients.
Economic Factors: The company is facing economic uncertainties that could affect future operations and growth, particularly in the context of financing and capital resources.
Inventory Management: The company has accrued for slow-moving stock, indicating potential challenges in inventory management and sales efficiency.
Revenue Dependency: The cancellation of the Oranim deal has resulted in a significant decrease in revenue, highlighting the risks associated with dependency on specific agreements.
Focus on German Market: The company is concentrating resources on the German market, which has shown unprecedented growth since partial legalization in April 2024.
Sales Growth in Germany: Sales in Germany increased by over 200% in Q2 to $3.5 million and by 66% in Q3 to $5.8 million.
Integration of Teams: Full integration of German and Israeli teams is a priority to build a strong supply chain and improve resource efficiency.
New Product Launches: Three Israeli grown strains were launched in Q3, with plans for onboarding new suppliers.
Cost Management: Active cost management has led to a decrease in operating expenses from $4.9 million in Q3 2023 to $4.1 million in Q3 2024.
Revenue Expectations for 2025: The company aims for accelerated growth in Germany in 2025, supported by a solid foundation built in 2024.
Operating Expenses Ratio: Operating expenses ratio improved to 30% in Q3 2024 from 40% in Q3 2023, indicating increased efficiency.
Future Financial Projections: The company plans to finance operations through existing resources and evaluate additional capital sources as needed.
Shareholder Return Plan: None
The earnings call reflects mixed signals: improved EBITDA and revenue growth in Germany, but significant net loss and inventory challenges. Regulatory changes in Germany and competitive pressures add uncertainty. The Q&A highlighted management's unclear responses, especially regarding margins. Despite some positive financial trends, the lack of a share repurchase program and cash position concerns suggest a cautious outlook, leading to a neutral sentiment.
The earnings call summary presents a mixed picture. Positive aspects include a 53% reduction in operating expenses, positive adjusted EBITDA in Q4, and strong revenue growth in Germany. However, challenges like competitive pressures, supply chain issues, and a significant inventory write-off pose risks. The Q&A section reveals concerns about market dynamics and margin progression, with unclear guidance. Financial health is stable but not robust. Overall, the sentiment is neutral, with no strong catalysts for significant stock price movement.
The earnings call presents mixed signals. Positive factors include strong growth in the German market, improved operational efficiency, and reduced losses. However, risks like supply chain challenges, regulatory issues, and competitive pressures counterbalance these positives. No guidance was provided, and there is no share buyback program to boost investor confidence. Given these factors, the stock price is likely to remain stable, resulting in a neutral prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
